-
AASLD 2023 | Professor Zhihua Liu’s Team: Revealing the Dynamic Changes in T-Cell Immunity during Pregnancy and Postpartum Period in Women with Chronic HBV Infection and Its Relationship with Infection Status
The natural history of chronic HBV infection primarily depends on the interaction between the host’s immune system and the virus. Pregnancy is a unique physiological process during which the mother’s…
-
IAS 2023 | Short-course tuberculosis (TB) preventive treatment does not affect the virologic efficacy of INSTIs in treating HIV
People Living With HIV (PLWH) are at high risk of active tuberculosis (TB). Guidelines both domestically and internationally suggest that PLWH with positive latent tuberculosis infection (LTBI) screening and those with a history of close contact with active TB should receive TB preventive treatment. However, commonly used preventive treatment regimens such as rifampin and rifapentine…
-
IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”
Integrase strand transfer inhibitors (INSTIs) are associated with weight gain, but this weight gain doesn’t harm survival or increase cardiovascular disease (CVD) risk. So, does the weight gain associated with INSTIs lead to a higher risk of diabetes? At the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), the renowned RESPOND cohort…
-
Dr. Wai-Kay Seto’s team: Multiple Studies on Hepatic Diseases Management with New Hepatitis B Drugs, Fatty Liver Monitoring, and Liver Cancer Risk Factors
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL2023) and the EASL Congress 2023 have come to a close. During this conference, Dr. Wai-Kay…
-
ASCO China Voice | Professor Jiang Zefei: Progress or Decrease in Risk of Death by 35%, TORCHLIGHT Shines Light on Chinese TNBC
Tumor Outlook: Please provide some background on the TORCHLIGHT study in the context of the current status of breast cancer immunotherapy both domestically and internationally. How did you overcome challenges…
-
Professor Jiang Zefei: Advances in the Treatment of Triple-Negative Breast Cancer
Tumor Outlook: There have been several notable research findings in the field of TNBC treatment in 2023. Could you please review and interpret them for us? Professor Jiang Zefei: Over…
-
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
The TORCHLIGHT study assessed the efficacy and safety of first-line treatment with Toripalimab plus nab-paclitaxel (n=353; experimental group) compared to placebo plus nab-paclitaxel (n=178; control group) in female patients with…
-
TED TALK | Professor Jiang Zefei: From Treatment to Cure in HER2-Positive Breast Cancer
“Women are the sky, and men are the earth. Only when women are well, can men stand tall.” Under the spotlight, Professor Jiang Zefei slowly stepped onto the center stage.…
Connecting Medical Expertise through Media